DEXACORT
LOE ApproachingNDANASALAEROSOL
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a nasal aerosol small-molecule corticosteroid approved in 1965 by UCB Pharma. The exact indications are not specified in available data, but nasal corticosteroids are typically used for allergic rhinitis, nasal polyps, and chronic rhinosinusitis. The drug works by reducing inflammation through glucocorticoid receptor activation in nasal tissues.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand is in transition mode; expect rightsizing of commercial teams and shift toward lifecycle extension initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DEXACORT offers limited growth trajectory but stable operational experience in a mature market. This role is best suited for professionals experienced in defending market share, managing generic erosion, and optimizing profitability in declining categories.
Brand ManagerField Sales Representative
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.